Stocks from the Smallcap Recap Report - May part I
. . . Launch leads to record sales - American Pharmaceutical Partners (Nasdaq: APPX) reported record first quarter net sales of $120.7 million for the quarter ended March 31, 2005, a 35% increase over net sales in the 2004 first quarter. Net income for the quarter was a quarterly record and gross margin increased to 62.4% versus 49.8% in the year ago quarter. The company attributes most of the increase to the launch of ABRAXANE for the treatment of metastatic breast cancer. American Pharmaceutical Partners develops injectable pharmaceutical products, focusing on the oncology, anti-infective and critical care markets.
. . . Chinese Pickup - Pickups Plus (OTC BB: PUPS) has signed a Letter of Intent to form a joint venture in the People's Republic of China which will market and distribute its ValuGard(TM) line of car care and environmental protection products in the PRC. The objective is to capitalize on China's growing automobile industry, which is expected to be on the forefront of the country's rapid industrialization and modernization. As millions of Chinese leave their bicycles and take to automobiles, the car care sector will see rapid growth.
. . . Better Bomb Detection - HiEnergy Technologies (OTCBB:HIET) has more than doubled the safety factor of its SIEGMA(TM) 3E3 homemade bomb detector. The improvement is a result of cutting by more than half the detector's potential to make "false negative" and "false positive" identifications from a level of 5% to 2.25%. One of the most dangerous consequences of false negatives, also known as the "missing fraction," is that they lead to a false sense of security. False negative means that true bombs are mislabeled as non-explosives, and can increase the chances of fatal accidents. HiEnergy has recently demonstrated its technology in front of audiences from the DoD and the FBI. Siemens provides aftermarket maintenance and servicing for HiEnergy Products.
. . . Mobilizing against Meningitis - EndoBiologics believes it has developed a novel and promising technology to treat meningitis. And so does VaxGen (Pink Sheets: VXGN.PK), so it has formed a collaboration to pursue research of this new treatment. VaxGen will fund proof-of-concept studies and has an exclusive option to continue product development if the studies yield promising results. Currently there is no licensed vaccine that has shown protection against a wide range of Meningitis B strains, a life-threatening disease most common in young children.
. . . Healthy gain for HealtheTech - Wellness is doing very well, and by extension, so are some of the companies providing health measurement tools. 2005 first quarter revenues for HealtheTech (Pink Sheets: HETC), a maker of proprietary handheld medical devices and software for the measurement of resting metabolic rate and nutrition monitoring, increased 64% over the same period last year. The company attributes the increase to the implementation of a more targeted strategy addressing commercial fitness, medically supervised weight management and corporate wellness markets.
. . . Promising lung drug study -InterMune (ITMN:Nasdaq) announced results of a Phase II clinical that showed its experimental drug pirfenidone successfully delayed the progression of idiopathic pulmonary fibrosis, an inflammatory lung disease. The disease is characterized by abnormal formation of lung tissue, causing coughing and shallow breathing after moderate exercise due to a lack of oxygen intake from the lungs. There are currently no drugs approved by the FDA for the treatment of IPF.
. . . More fuel for the hydrogen movement - Apollo Alternative Fuels Company, LLC, a wholly-owned subsidiary of Apollo Resources International (OTCBB:AOOR), has completed a stock purchase agreement with Energy Ventures Organization, Inc., a pioneer in the fast growing hydrogen fuels industry. Under the agreement, Apollo Alternative Fuels owns 50% of the stock in Energy Ventures. Recent headlines as well as initiatives by the Bush administration and states such as California have fueled the momentum of the development of hydrogen as an alternative energy source.
. . . Smarter hearts - American Scientific Resources (PNK: ASFX) has launched its flagship Heart Smart System(TM), a line of nutraceutical products that assist in the successful prevention of cardiovascular disease. The Heart Smart System(TM) is a nutritional line of supplements which support and maintain a healthy heart by rejuvenating the body's supply of Coenzyme Q10 (CoQ10). The company's product line intersects two major markets in the healthcare field, nutraceuticals and cardiovascular disease prevention.
. . . Steelmaker nearly triples profits - Ryerson Tull (NYSE: RT), a processor and distributor of steel and other metals, reported that first-quarter profits nearly tripled and revenue more than doubled. Much of the increase is attributed to company's acquisition of Integris Metals. JP Morgan has upgraded Ryerson to an Overweight rating.
. . . New obesity treatment - Manhattan Pharmaceuticals (OTCBB: MHTT) has concluded its Phase 1a trial and begun patient dosing in the Phase 1b trial to evaluate the safety and tolerability of defined doses of orally administered Oleoyl estrone (OE) in obese adults. Oleoyl estrone is believed to be a signaling molecule that acts on the brain to communicate satiety. It is hypothesized that in obese individuals circulating OE levels are lower than would be expected for the level of body fat. Orally administered formulations of OE has been demonstrated, in extensive preclinical animal studies, to cause significant weight loss and reduced caloric consumption without the need for dietary modifications.
Get the SCOOP with our FREE NEWSLETTER
. . . Chinese Pickup - Pickups Plus (OTC BB: PUPS) has signed a Letter of Intent to form a joint venture in the People's Republic of China which will market and distribute its ValuGard(TM) line of car care and environmental protection products in the PRC. The objective is to capitalize on China's growing automobile industry, which is expected to be on the forefront of the country's rapid industrialization and modernization. As millions of Chinese leave their bicycles and take to automobiles, the car care sector will see rapid growth.
. . . Better Bomb Detection - HiEnergy Technologies (OTCBB:HIET) has more than doubled the safety factor of its SIEGMA(TM) 3E3 homemade bomb detector. The improvement is a result of cutting by more than half the detector's potential to make "false negative" and "false positive" identifications from a level of 5% to 2.25%. One of the most dangerous consequences of false negatives, also known as the "missing fraction," is that they lead to a false sense of security. False negative means that true bombs are mislabeled as non-explosives, and can increase the chances of fatal accidents. HiEnergy has recently demonstrated its technology in front of audiences from the DoD and the FBI. Siemens provides aftermarket maintenance and servicing for HiEnergy Products.
. . . Mobilizing against Meningitis - EndoBiologics believes it has developed a novel and promising technology to treat meningitis. And so does VaxGen (Pink Sheets: VXGN.PK), so it has formed a collaboration to pursue research of this new treatment. VaxGen will fund proof-of-concept studies and has an exclusive option to continue product development if the studies yield promising results. Currently there is no licensed vaccine that has shown protection against a wide range of Meningitis B strains, a life-threatening disease most common in young children.
. . . Healthy gain for HealtheTech - Wellness is doing very well, and by extension, so are some of the companies providing health measurement tools. 2005 first quarter revenues for HealtheTech (Pink Sheets: HETC), a maker of proprietary handheld medical devices and software for the measurement of resting metabolic rate and nutrition monitoring, increased 64% over the same period last year. The company attributes the increase to the implementation of a more targeted strategy addressing commercial fitness, medically supervised weight management and corporate wellness markets.
. . . Promising lung drug study -InterMune (ITMN:Nasdaq) announced results of a Phase II clinical that showed its experimental drug pirfenidone successfully delayed the progression of idiopathic pulmonary fibrosis, an inflammatory lung disease. The disease is characterized by abnormal formation of lung tissue, causing coughing and shallow breathing after moderate exercise due to a lack of oxygen intake from the lungs. There are currently no drugs approved by the FDA for the treatment of IPF.
. . . More fuel for the hydrogen movement - Apollo Alternative Fuels Company, LLC, a wholly-owned subsidiary of Apollo Resources International (OTCBB:AOOR), has completed a stock purchase agreement with Energy Ventures Organization, Inc., a pioneer in the fast growing hydrogen fuels industry. Under the agreement, Apollo Alternative Fuels owns 50% of the stock in Energy Ventures. Recent headlines as well as initiatives by the Bush administration and states such as California have fueled the momentum of the development of hydrogen as an alternative energy source.
. . . Smarter hearts - American Scientific Resources (PNK: ASFX) has launched its flagship Heart Smart System(TM), a line of nutraceutical products that assist in the successful prevention of cardiovascular disease. The Heart Smart System(TM) is a nutritional line of supplements which support and maintain a healthy heart by rejuvenating the body's supply of Coenzyme Q10 (CoQ10). The company's product line intersects two major markets in the healthcare field, nutraceuticals and cardiovascular disease prevention.
. . . Steelmaker nearly triples profits - Ryerson Tull (NYSE: RT), a processor and distributor of steel and other metals, reported that first-quarter profits nearly tripled and revenue more than doubled. Much of the increase is attributed to company's acquisition of Integris Metals. JP Morgan has upgraded Ryerson to an Overweight rating.
. . . New obesity treatment - Manhattan Pharmaceuticals (OTCBB: MHTT) has concluded its Phase 1a trial and begun patient dosing in the Phase 1b trial to evaluate the safety and tolerability of defined doses of orally administered Oleoyl estrone (OE) in obese adults. Oleoyl estrone is believed to be a signaling molecule that acts on the brain to communicate satiety. It is hypothesized that in obese individuals circulating OE levels are lower than would be expected for the level of body fat. Orally administered formulations of OE has been demonstrated, in extensive preclinical animal studies, to cause significant weight loss and reduced caloric consumption without the need for dietary modifications.
Get the SCOOP with our FREE NEWSLETTER
posted by laltman at 10:21 AM
0 comments
